Answers are grounded in this paper and cite their sources.
Objective International guidelines recommend molecular classification of endometrial cancer into 4 subtypes: polymerase ε ( POLE ) mutated, mismatch repair-deficient (dMMR), p53-abnormal, and no specific molecular profile. However, implementation of molecular classification is often incomplete due to limited access to POLE testing. For dMMR tumors, MLH1 promoter methylation testing is used to triage sporadic MLH1 loss before germline testing for Lynch syndrome, but its unavailability leads to inconsistent screening practices. This study evaluated real-world adherence to National Comprehensive Cancer Network guidelines regarding molecular risk stratification and Lynch syndrome screening.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: